Dr. Xuetao Cao graduated from the Second Military Medical University (SMMU), Shanghai, China in 1986 and received his Ph.D. in Immunology from SMMU in 1990. From 1992, he became the Professor in Immunology at the Department of Immunology, SMMU. He is now the Director of the Institute of Immunology at the SMMU. He is also the Director of the Institute of Immunology at Zhejiang University, Hangzhou, China. He is the Managing Editor-in-Chief of Chinese Journal of Cancer Biotherapy, the President of Committee of Tumor Immunology and Biotherapy, Chinese Association of Immunology, and the chief scientist of the National Key Basic Research Program (973) in Immunology. His field is the tumor immunology and immunotherapy. He investigated cancer immunotherapy using cytokine gene-modified vaccines. In recent years, his research focuses on the dendritic cell-based immunotherapy and gene therapy of cancer. He also reported the discovery of novel full-length cDNAs from human dendritic cell cDNA library by large-scale random sequencing, for example, he found a new member of HSP70 subfamily HSP-DC which activates dendritic cells and acts as potent Th1 polarized adjuvant, a new member of MIP-2 which chemoattracts neutrophiles and dendritic cells. He published more than 70 papers in the international journals including J Immunol, Cancer Res, J Biol Chem, Huamn Gene Therapy, Gene Therapy.